REGENXBIO announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene.  “Our NAV technology platform holds tremendous promise for advancing this new product candidate in our neurodegenerative disease pipeline,” said Olivier Danos, Ph.D., senior vice president and chief scientific off...